154287-27-1

Upstream product

• 624-38-4 para-diiodobenzene 
• 154287-26-0 1-<4-(3-chlorobutoxy)phenyl>-2-phenyl-1-butanone 

Relevant academic research and scientific papers

Substituted 1,1,2-triphenylbutenes and their use in the treatment of cancer

Compounds of the general formula (2) STR1 wherein n is an integer of from 3 to 10, the iodo substituent is in the 3- or 4-position and R 1 and R 2, which may be the same or different, represent C 1-3 alkyl, especially methyl or ethyl, groups or R l represents a hydrogen atom and R 2 a C 1-3 alkyl group or R 1 and R 2 together with the nitrogen atom to which they are attached represent a saturated heterocyclic group, especially a pyrrolidino group, in the form of their free bases or pharmaceutically acceptable acid addition salts are potent anti-oestrogenic compounds useful for treatment of oestrogen-dependent cancers, especially breast cancers. Compounds where the iodine atom is radioisotopic are useful in radiotherapy or gamma ray imaging of these cancers.

Rationally designed analogues of tamoxifen with improved calmodulin antagonism

Computerized molecular modeling studies on the interactions of the antiestrogen tamoxifen (1) and its analogues bound to the calcium-binding protein calmodulin have guided the rational design of more potent antagonists. Compounds with either three or four methylene units in the basic side chain or slim lipophilic 4-substituents were expected to be more potent. All compounds were tested for antagonism of the calmodulin-dependent activity of cAMP phosphodiesterase and for binding affinity to the estrogen receptor from rat uteri. Some compounds were assayed for cytotoxicity against MCF-7 breast tumor cells in vitro. Introduction of lipophilic 4-substituents was accomplished by using palladium(0)-catalyzed coupling reactions with a 4- iodinated precursor. Both the 4-ethynyl (16 and 17) and 4-butyl (18 and 19) compounds were more potent calmodulin antagonists than tamoxifen. Extension of the basic aminoethoxy side chain of 4-iodotamoxifen (3) and idoxifene (2) ((E)-1-[4-[2-(N-pyrrolidino)ethoxy]phenyl]-1-(4-iodophenyl)-2-phenyl-1- butene) by one or two methylene units resulted in modest gains in calmodulin antagonism (10-13). All the compounds assayed retained estrogen receptor binding characteristics. The compound possessing the optimal combination of calmodulin antagonism and estrogen receptor binding was 12 ((E)-1-[4-[3-(N- pyrrolidino)propoxy]phenyl]-1-(4-iodophenyl)-2-phenyl-1-butene)(IC50 = 1.1 μM, RBA= 23). Correlation between calmodulin antagonism and cytotoxicity was demonstrated for selected compounds.